Dw. End, Farnesyl protein transferase inhibitors and other therapies targeting the ras signal transduction pathway, INV NEW DR, 17(3), 1999, pp. 241-258
The year 2000 will be a significant date for the field of Ras-related thera
pies since numerous agents will have Phase II clinical efficacy data maturi
ng to provide proof of principle for this cancer treatment strategy. These
data will also provide an important milestone for the cancer research commu
nity since these molecules represent a small vanguard of oncology drug disc
overy projects predicated on molecular targets. We can only hope that these
agents are a successful harbinger for the formidable number of targeted th
erapies that will be entering development pipelines in the coming years.